Insmed Incorporated (NASDAQ:INSM) Given Consensus Recommendation of “Buy” by Analysts

Insmed Incorporated (NASDAQ:INSM) has been given a consensus rating of “Buy” by the ten research firms that are presently covering the company, Marketbeat.com reports. Ten research analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have covered the stock in the last year is $45.10.

INSM has been the subject of a number of recent analyst reports. Wells Fargo & Company restated an “overweight” rating and set a $55.00 target price on shares of Insmed in a report on Monday, April 1st. UBS Group initiated coverage on Insmed in a report on Tuesday, February 27th. They set a “buy” rating and a $46.00 target price for the company. StockNews.com upgraded Insmed from a “sell” rating to a “hold” rating in a report on Wednesday, February 28th. Wolfe Research initiated coverage on Insmed in a report on Thursday, February 15th. They set an “outperform” rating and a $42.00 target price for the company. Finally, Guggenheim upped their target price on Insmed from $52.00 to $54.00 and gave the company a “buy” rating in a report on Tuesday, February 27th.

Insmed Stock Performance

Shares of INSM stock opened at $27.66 on Friday. Insmed has a fifty-two week low of $16.25 and a fifty-two week high of $32.00. The stock has a 50 day moving average price of $27.70 and a two-hundred day moving average price of $26.94. The company has a market capitalization of $4.11 billion, a P/E ratio of -5.18 and a beta of 0.92.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, missing the consensus estimate of ($1.13) by ($0.15). The business had revenue of $83.70 million during the quarter, compared to analysts’ expectations of $82.15 million. During the same period in the prior year, the firm earned ($1.20) EPS. The business’s revenue was up 41.1% on a year-over-year basis. As a group, equities analysts predict that Insmed will post -4.65 earnings per share for the current year.

Insiders Place Their Bets

In other news, VP Michael Alexander Smith sold 2,373 shares of the stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $28.76, for a total value of $68,247.48. Following the sale, the vice president now directly owns 86,364 shares of the company’s stock, valued at $2,483,828.64. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, VP Michael Alexander Smith sold 2,373 shares of the stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $28.76, for a total value of $68,247.48. Following the sale, the vice president now directly owns 86,364 shares of the company’s stock, valued at $2,483,828.64. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Martina M.D. Flammer sold 4,667 shares of the stock in a transaction on Friday, January 12th. The stock was sold at an average price of $28.63, for a total value of $133,616.21. Following the completion of the sale, the insider now directly owns 106,898 shares in the company, valued at $3,060,489.74. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 67,606 shares of company stock worth $1,977,998. 4.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Insmed

Institutional investors have recently modified their holdings of the business. Walleye Capital LLC purchased a new stake in shares of Insmed during the third quarter valued at $1,820,000. Graham Capital Management L.P. boosted its position in shares of Insmed by 352.5% during the third quarter. Graham Capital Management L.P. now owns 43,605 shares of the biopharmaceutical company’s stock valued at $1,101,000 after buying an additional 33,969 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Insmed by 7.7% during the third quarter. Vanguard Group Inc. now owns 14,345,512 shares of the biopharmaceutical company’s stock valued at $362,224,000 after buying an additional 1,024,956 shares during the last quarter. Trexquant Investment LP boosted its position in shares of Insmed by 898.8% during the third quarter. Trexquant Investment LP now owns 294,993 shares of the biopharmaceutical company’s stock valued at $7,449,000 after buying an additional 265,457 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Insmed by 8.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,099,807 shares of the biopharmaceutical company’s stock valued at $27,770,000 after buying an additional 88,589 shares during the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.